Pharmacists, Drug Regulators and AMA to Examine Medical Marijuana

As pharmacists and drug regulators from across the country convene in Tucson this week for their Winter symposium, they will be discussing medical marijuana, an issue which is headlining the agenda.

The National Association of Boards of Pharmacy (NABP) opens its symposium on Thursday with several presentations on medical marijuana by an array of speakers and experts, including Caren Woodson, Government Affairs Director with Americans for Safe Access, the country’s largest advocacy organization focused on the issue.

“We welcome the interest in medical marijuana by the Boards of Pharmacy and want to work with them to address this public health issue,” said Woodson. “State Boards of Pharmacy can have an impact on medical marijuana and we want to work with them to adopt sensible policies.” The Oregon Board of Pharmacy has been ordered to remove marijuana from its state list of Schedule I drugs, per legislation signed by Governor Kulongoski in August. In addition, the Iowa Board of Pharmacy is currently considering rescheduling marijuana as a result of litigation.

Woodson will co-present on a panel Thursday morning with Barry D. Dickinson, the Director of Science & Biotechnology for the American Medical Association, and Alice Mead, the Director of U.S. Public Relations for GW Pharmaceuticals, a U.K. company conducting clinical trials for a medical marijuana extract. The panel is entitled, “Should Marijuana be a Medical Option?” Later, Woodson will take part in a point-counterpoint on medical marijuana with Dickinson, Mead and other experts, including Andrea Barthwell, former deputy director for the U.S. Office of National Drug Control Policy and other marijuana researchers.

The NABP symposium will be attended by Boards of Pharmacy executive officers, members, and other state and federal regulators as well as stakeholders in the pharmaceutical industry. Both the California Attorney General’s office and the California Department of Public Health are sending representatives to the symposium. Attendees will be able to earn continuing pharmacy education credit for their participation in medical marijuana panels.

The mission of the NABP is to assist its member boards in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health. The State Boards of Pharmacy oversee the classification of controlled substances, such as marijuana, at the state level, similar to the way that the Food & Drug Administration (FDA) and the Drug Enforcement Administration (DEA) oversee the federal classification of controlled substances. While state controlled substance lists routinely match the federal list, the State Boards of Pharmacy can change the classification of particular drugs independent of the federal government.

The NABP symposium follows a report on medical marijuana issued last month by the American Medical Association, in which the oldest and largest physician-based group in the U.S. urged the federal government to review the Schedule I status for marijuana. The AMA noted that marijuana appeared to be efficacious for several health conditions and said that further research was needed to assess whether marijuana should continue to be considered a dangerous drug with no medical value.

– Article from Americans for Safe Access.

Comments

4 Comments

  1. Anonymous on

    I would think that if cannabis is rescheduled, there would have to be early releases. Why? Rescheduling in tennement to admitting the law was wrong, how can you keep people imprisoned over a law that was wrong. I for one would be filing a law suit if I were in prison or jail. This isnt a traffic ticket were talking about, it a life.

    As far a bigpharma trying to change cannabis to suit their needs, I say grab up all the pure seed you can and start growing. Keep in natural.

  2. Theresa on

    I am quite disappointed that The State Boards of Pharmacy and the FDA are our obstacles. It is because of their Bush Big Pharma movement, I stopped using cannabis and started using DANGEROUS PRESCRIPTION DRUGS for a stomach disorder and ended up with a serious Excruciating and Relentless movement disorder. The Pharmaceutical companies are wanting to alter our cannabis. NO WAY!!!!!! I AM NOT ALONE HERE. PEOPLE ARE SICK AND TIRED OF THESE ORGANIZATIONS OFFERING UP THEIR POISONS. LEAVE OUR CANNABIS ALONE, IT’S ALL WE HAVE LEFT THAT IS PURE AND BENEFICIAL TO OUR ILLS.

  3. Dirty Harry on

    QUOTE:
    “The rescheduling of the drug will mean that the sentences must be reduced and therefore early release.The sweet smell of a taste of fredom.”
    __________________________
    I would hope so, but I doubt they would be retro active on existing charges. I think they would only apply “any” changes to new things.
    I know when they raised the speed limit on my road from 25 to 35, I didn’t get any ticket money back from past tickets for going over 25 but under 35.

    Still, its a good step forward.

  4. Jay Dell on

    The rescheduling of the drug will mean that the sentences must be reduced and therefore early release.The sweet smell of a taste of fredom.

    The mission of the NABP is to assist its member boards in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.

    SAFE AND CLEAN
    ORGANIC
    ADVANCED NUTRIENTS

    Crazy Bird